SG10201701954QA - Anti-cxcr1 compositions and methods - Google Patents

Anti-cxcr1 compositions and methods

Info

Publication number
SG10201701954QA
SG10201701954QA SG10201701954QA SG10201701954QA SG10201701954QA SG 10201701954Q A SG10201701954Q A SG 10201701954QA SG 10201701954Q A SG10201701954Q A SG 10201701954QA SG 10201701954Q A SG10201701954Q A SG 10201701954QA SG 10201701954Q A SG10201701954Q A SG 10201701954QA
Authority
SG
Singapore
Prior art keywords
methods
cxcr1
compositions
cxcr1 compositions
Prior art date
Application number
SG10201701954QA
Inventor
Max S Wicha
Christophe Ginestier
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of SG10201701954QA publication Critical patent/SG10201701954QA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG10201701954QA 2008-11-11 2009-11-11 Anti-cxcr1 compositions and methods SG10201701954QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11345808P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
SG10201701954QA true SG10201701954QA (en) 2017-05-30

Family

ID=42170302

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201701954QA SG10201701954QA (en) 2008-11-11 2009-11-11 Anti-cxcr1 compositions and methods

Country Status (26)

Country Link
US (3) US8940301B2 (en)
EP (2) EP3153862A1 (en)
JP (3) JP5716180B2 (en)
KR (3) KR20110093893A (en)
CN (3) CN104623664B (en)
AU (1) AU2009314141B2 (en)
BR (1) BRPI0921150B1 (en)
CA (1) CA2743305C (en)
CY (1) CY1118933T1 (en)
DK (1) DK2356462T3 (en)
EA (1) EA023466B1 (en)
ES (1) ES2623128T3 (en)
HK (3) HK1206256A1 (en)
HR (1) HRP20170463T1 (en)
HU (1) HUE032623T2 (en)
IL (1) IL212822A (en)
LT (1) LT2356462T (en)
MX (2) MX2011005007A (en)
NZ (2) NZ625440A (en)
PL (1) PL2356462T3 (en)
PT (1) PT2356462T (en)
RS (1) RS55784B1 (en)
SG (1) SG10201701954QA (en)
SI (1) SI2356462T1 (en)
WO (1) WO2010056753A1 (en)
ZA (1) ZA201103416B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104623664B (en) 2008-11-11 2018-08-07 密歇根大学董事会 Anti- CXCR1 compositions and method
GB201106870D0 (en) * 2011-04-26 2011-06-01 Univ Belfast Marker
WO2013067055A1 (en) * 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
CN103159650B (en) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 The preparation of aromatic heterocycle sulfamide compound and application thereof
CN103159649B (en) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 The preparation of sulfamide compound and application thereof
WO2013144240A1 (en) * 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
ES2728305T3 (en) * 2013-04-29 2019-10-23 Ogd2 Pharma Use as an O-acetylated GD2 ganglioside target as a new therapeutic and diagnostic strategy for cancer stem cell cancer
JP6683986B2 (en) * 2013-07-10 2020-04-22 国立大学法人 東京大学 Cancer stem cell molecular marker
US11291641B2 (en) 2016-10-03 2022-04-05 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy
CA3044030A1 (en) * 2016-11-17 2018-05-24 Nantbio, Inc. Validation of inferred anticancer pathways
AU2017370942A1 (en) 2016-12-07 2019-06-13 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10100275B2 (en) 2017-03-16 2018-10-16 King Faisal Specialist Hospital & Research Centre Method for generating human multipotent mammary stem cells from normal primary breast luminal cells
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
RU2702910C2 (en) * 2018-12-20 2019-10-14 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Method for reducing the number of stem cells of breast cancer
WO2020172233A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Treatment of prostate cancer by androgen ablation and il-8 blockade
RU2700695C2 (en) * 2019-02-27 2019-09-19 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Method for reducing clonogenic activity of lacteal gland cancer stem cells
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP2021109877A (en) * 2020-01-10 2021-08-02 北京鋭瑟生物醫薬科技發展有限公司 Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
CN114075286A (en) * 2020-08-21 2022-02-22 张家港博泽利斯生物技术有限公司 Preparation method of anti-human CXCR1 protein monoclonal antibody
WO2023032957A1 (en) * 2021-08-30 2023-03-09 学校法人東京薬科大学 Pharmaceutical composition for prevention and/or treatment of cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69326967T2 (en) 1992-01-17 2000-06-15 Lakowicz Joseph R Phase modulation energy transfer fluoroimmunoassay
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
ATE316573T1 (en) 1992-10-30 2006-02-15 Gen Hospital Corp INTERACTING TRAP SYSTEM FOR ISOLATION OF PROTEINS
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6156305A (en) 1994-07-08 2000-12-05 Baxter International Inc. Implanted tumor cells for the prevention and treatment of cancer
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6207147B1 (en) 1996-10-11 2001-03-27 The Regents Of The University Of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6582904B2 (en) * 1995-11-16 2003-06-24 Michael W. Dahm Method of quantifying tumour cells in a body fluid and a suitable test kit
EP0874993A1 (en) 1995-12-22 1998-11-04 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
CA2283267A1 (en) 1997-03-07 1998-09-11 Clare Chemical Research Llc Fluorometric detection using visible light
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
WO2002062850A2 (en) * 2001-02-02 2002-08-15 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
AU2002364537A1 (en) 2001-12-07 2003-06-23 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
AU2003291549A1 (en) * 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
PT1629088E (en) * 2003-05-30 2012-04-10 Agensys Inc Prostate stem cell antigen (psca) variants and subsequences thereof
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050142136A1 (en) * 2003-10-23 2005-06-30 Lary Suva Anti-interleukin 8 therapy for tumor osteolysis
US20050232927A1 (en) 2004-02-03 2005-10-20 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2005103711A2 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)
WO2005113534A2 (en) 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
GB0417740D0 (en) * 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
CA2628255C (en) 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070208074A1 (en) * 2006-01-24 2007-09-06 Bonni Azad M Methods and compositions for treating and preventing tumors
UA98456C2 (en) 2006-04-21 2012-05-25 Смитклайн Бичам Корпорейшн Il-8 receptor antagonists
WO2008036419A2 (en) 2006-09-22 2008-03-27 The Regents Of The University Of Michigan Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker
JP5311439B2 (en) * 2006-12-27 2013-10-09 日本メナード化粧品株式会社 Method for evaluating skin condition and use thereof
CN101126758A (en) * 2007-09-06 2008-02-20 江苏省肿瘤医院 Flow cytometry synchronous detection method for multiple protein expression of tumor cell
WO2010009121A2 (en) * 2008-07-15 2010-01-21 University Of Florida Research Foundation, Inc. Colon stem cells associated with colitis and colorectal cancer and methods of use
CN104623664B (en) 2008-11-11 2018-08-07 密歇根大学董事会 Anti- CXCR1 compositions and method

Also Published As

Publication number Publication date
HK1206256A1 (en) 2016-01-08
CN104634972A (en) 2015-05-20
JP2016065082A (en) 2016-04-28
CN104634972B (en) 2017-06-13
CA2743305A1 (en) 2010-05-20
US10557850B2 (en) 2020-02-11
CN102272599A (en) 2011-12-07
PT2356462T (en) 2017-04-07
EP2356462B1 (en) 2017-01-04
CN102272599B (en) 2015-01-14
HRP20170463T1 (en) 2017-05-19
EP2356462A1 (en) 2011-08-17
US20150094362A1 (en) 2015-04-02
NZ602369A (en) 2015-02-27
JP5909783B2 (en) 2016-04-27
JP5716180B2 (en) 2015-05-13
CA2743305C (en) 2017-04-04
AU2009314141A1 (en) 2010-05-20
CN104623664A (en) 2015-05-20
HK1206421A1 (en) 2016-01-08
DK2356462T3 (en) 2017-02-27
NZ625440A (en) 2016-01-29
US8940301B2 (en) 2015-01-27
KR20150065930A (en) 2015-06-15
LT2356462T (en) 2017-03-10
KR20140132412A (en) 2014-11-17
US9606124B2 (en) 2017-03-28
US20100136031A1 (en) 2010-06-03
EA201100779A1 (en) 2011-12-30
AU2009314141B2 (en) 2013-11-07
HUE032623T2 (en) 2017-10-30
BRPI0921150B1 (en) 2022-05-10
KR101588547B1 (en) 2016-01-28
US20150160227A1 (en) 2015-06-11
RS55784B1 (en) 2017-07-31
BRPI0921150A2 (en) 2020-11-17
EA023466B1 (en) 2016-06-30
ES2623128T3 (en) 2017-07-10
SI2356462T1 (en) 2017-05-31
HK1161350A1 (en) 2012-08-24
JP2014037427A (en) 2014-02-27
IL212822A (en) 2017-05-29
PL2356462T3 (en) 2017-07-31
MX351889B (en) 2017-11-01
WO2010056753A1 (en) 2010-05-20
CN104623664B (en) 2018-08-07
KR20110093893A (en) 2011-08-18
EP3153862A1 (en) 2017-04-12
CY1118933T1 (en) 2018-01-10
IL212822A0 (en) 2011-07-31
MX2011005007A (en) 2011-07-28
JP2012508384A (en) 2012-04-05
EP2356462A4 (en) 2012-09-19
ZA201103416B (en) 2012-08-29

Similar Documents

Publication Publication Date Title
IL210153A0 (en) Nutrigenomics methods and compositions
IL212822A0 (en) Anti-cxcr1 compositions and methods
ZA201001300B (en) Antigen-asjuvant compositions and methods
GB0819530D0 (en) Methods and compositions
GB0815872D0 (en) Novel method and compositions
FI3812360T3 (en) Monochlorotrifluoropropene compounds and compositions and methods using same
ZA201003696B (en) Compositions and devices
IL210559A0 (en) Novel compositions and methods
IL210588A0 (en) Novel compositions and methods
IL211204A0 (en) Mucoadherents compositions and their use
GB0721291D0 (en) Methods and compositions
TWI367763B (en) Compositions and devices
GB0903299D0 (en) Composition and methods
GB0817585D0 (en) Novel compositions and methods
GB0719526D0 (en) Compositions and methods
GB0901494D0 (en) Compositions and Methods
GB0811250D0 (en) Methods and compositions
GB0811152D0 (en) Methods and compositions
GB0803464D0 (en) Methods and compositions
GB0818399D0 (en) Methods and compositions
GB0816534D0 (en) Compositions and methods
GB0802079D0 (en) Method and compositions
GB0724549D0 (en) Compositions and methods
GB0723775D0 (en) Methods and compositions
GB0717683D0 (en) Compositions and methods